In the past weekend, covid-19 industrial chain was full of good news.
On the evening of February 20, Asymchem Laboratories (Tianjin) Co.Ltd(002821) announced that the company signed another large order with a contract amount of 3.542 billion yuan.
On the same day, Nanjing Hicin Pharmaceutical Co.Ltd(300584) and Shan Dong Kexing Bioproducts Co.Ltd(688136) also issued announcements one after another. Among them, Nanjing Hicin Pharmaceutical Co.Ltd(300584) said that the anti covid-19 drug nimatovir API and its key intermediate project were filed; Shan Dong Kexing Bioproducts Co.Ltd(688136) said to cooperate in the development of small oral drugs against covid-19 virus.
Just the day before (February 19), China approved covid-19 vaccine “mixed injection” booster, with Zhifei or Cansino Biologics Inc(688185) vaccine.
cdmo company’s frequent orders + upstream company’s overweight capacity
On the evening of February 20, it was announced that in the process of continuously providing contract customized R & D and production (cdmo) services for a small molecule chemical innovative drug of a pharmaceutical company (hereinafter referred to as the “customer”), Jilin Asymchem Laboratories (Tianjin) Co.Ltd(002821) Pharmaceutical Chemistry Co., Ltd., a wholly-owned subsidiary of the company, recently signed a new batch of supply contracts for related products with customers, The contract amount is equivalent to about 3.542 billion yuan. The new supply contract has come into force after being signed and sealed by both parties. The company said that if the contract is successfully performed and the delivery time is 2022, it is expected to have a positive impact on the company’s financial situation and operating results in 2022.
Asymchem Laboratories (Tianjin) Co.Ltd(002821) has successively signed major contracts for daily operation in 2021, with the amount of US $481 million and RMB 2.72 billion respectively. However, the company did not disclose the basic information of the counterparty and product related information according to the relevant agreements signed between the company and its customers due to the confidentiality of trade secrets involved in the transaction.
It is generally believed in the industry that the order comes from Pfizer covid-19 oral medicine. In this regard, the person from the Securities Department of the company previously responded to the China Securities Journal Taurus reporter that the company’s orders and research projects are not allowed to disclose the name of customers, treatment fields and drug names. Among the top 20 pharmaceutical companies in the world, 15 are customers of the company, such as Pfizer, Eli Lilly, MSD, etc.
Driven by the accelerated research and development of covid-19 small molecule oral drugs in the world, China cdmo company has received orders continuously. Previously, Porton Pharma Solutions Ltd(300363) announced that it had received US $681 million purchase orders from Pfizer’s companies.
In addition, in terms of the layout of raw materials and intermediates, Nanjing Hicin Pharmaceutical Co.Ltd(300584) announced on the evening of February 20 that Anqing Huichen, a holding subsidiary, obtained the project record issued by the Economic Development Bureau of Anqing high tech Industrial Development Zone on February 18, 2022. The project name is “Anqing Huichen Pharmaceutical Co., Ltd. annual output of 100 tons of anti covid-19 drug nimatovir API and its key intermediates construction project”, The completion time of the project is 2022, and the total investment of the project is 50.08 million yuan. The source of funds is self raised by the company.
However, the company warned that the API of the project could not be sold because it involved patents. At present, it is only used by the company for scientific research. There is serious uncertainty about whether the project can achieve the company’s scientific research objectives in the future. The intermediates involved in this project are only sold in the non regulatory market. At present, there is no fixed order, and the company has no commercial cooperation with Pfizer. The channel of 6,6-dimethyl-3-azabicyclo (3.1.0) hexane (CAS No.: 943516-54-9), the raw material required for the synthesis of the intermediate, is still unstable, the price fluctuates, and the income after the project is put into operation in the future is uncertain.
covid-19 double acceleration of prevention and treatment
Shan Dong Kexing Bioproducts Co.Ltd(688136) it was announced on the evening of February 20 that Shenzhen Kexing, a wholly-owned subsidiary of the company, signed the shen26 project cooperation agreement with antaiway on February 18, 2022. Globally, antaiway exclusively licensed the shen26 intellectual property rights it obtained or held to Shenzhen Kexing, and transferred the follow-up R & D rights and commercialization interests of products to Shenzhen Kexing. SHEN26 is a New Coronavirus polymerase (RdRp) inhibitor, which can achieve antiviral effect by inhibiting viral nucleic acid synthesis. At present, it has completed laboratory development, is undergoing pre clinical pharmacy and process development, and has submitted relevant patent applications. It has been included in the 2021 Guangdong prevention and control New Coronavirus infection science and technology emergency response special project.
In addition to covid-19 specific drugs, on February 19, China approved covid-19 vaccine “mixed injection” booster injection. Wu Liangyou, deputy director of the disease control bureau of the National Health Commission, said at the press conference of the joint prevention and control mechanism of the State Council that recently, with the approval of the joint prevention and control mechanism of the State Council, the National Health Commission has begun to deploy sequential immunization.
Previously, target people over 18 years old who have been vaccinated with inactivated vaccine of Sinopharm Zhongsheng Beijing company, Beijing Kexing company, Sinopharm Zhongsheng Wuhan company or adenovirus vector vaccine of Tianjin Cansino Biologics Inc(688185) company for 6 months can be immunized with one dose of primary homologous booster vaccine, that is, enhanced with protovaccine. After the implementation of the sequential booster immunization strategy, the target population who has completed the whole process of vaccination with the above three inactivated vaccines can also choose the recombinant protein vaccine of zhifeilongke horse or Cansino Biologics Inc(688185) adenovirus vector vaccine for sequential booster immunization.
On the evening of February 20th, Cansino Biologics Inc(688185) announced that as of now, the company’s recombinant New Coronavirus vaccine (type 5 adenovirus vector) (trade name: Ke Wei Sha) has been granted China’s conditional approval and emergency use authorization from many other countries. After the product is approved for sequential immunization, if the relevant national departments increase their procurement, it will have a certain positive impact on the performance of listed companies.
industrial chain enterprises are expected to benefit
On February 11, the State Food and Drug Administration conditionally approved the import registration of the combined packaging of nevitavir tablets / ritonavir tablets (i.e. paxlovid) of Pfizer’s covid-19 virus treatment drug, driving the continuous rise of covid-19 oral drug related companies in the near future.
According to capital securities, Pfizer expects the output of paxlovid to be 6 million courses in the first quarter of 2022, 30 million courses in the first half of 2022 and 120 million courses in the whole year (performance guidance of US $22 billion). With the increase of approved countries and the promotion of MPP agreement, based on 15% – 20% of drug production cost, the market scale of relevant industrial chain this year is US $3.3 billion-4.4 billion.
Capital Securities said that China’s supply chain systems of small molecule drug intermediates, API (active drug ingredients), preparations and other products are stable and mature, and relevant enterprises are expected to obtain large profits.
Industry insiders believe that the outbreak of covid-19 has brought a test to global economic activities, and the successive approval of vaccines, neutralizing antibodies and small molecular oral drugs constitute a complete closed loop for the prevention and control of covid-19. Covid-19 vaccine is combined with covid-19 specific drugs to realize the combination of prevention and treatment, and enhance the global response to covid-19 epidemic.
Sudden! Queen of England covid-19 positive! The 75 billion giant signed a big order. Domestic covid-19 oral medicine welcomes the good pharmaceutical stocks?
Hong Kong stocks and A-share biopharmaceutical sector strengthened against the trend! The concept of covid-19 medicine is frequently spread over the weekend to welcome the “heart booster”! (attached shares)
